12 results about "Silicosis" patented technology

The invention belongs to the technical field of animal model construction, and particularly relates to a method for constructing a silicosis-related atherosclerosis animal model. Comprising the following steps: after adaptive feeding of healthy mice, intragastric ursodeoxycholic acid is performed once, the mice are fed with high-fat feed and periodically subjected to nasal drop treatment by 50mg / mL SiO2 suspension for more than 10 weeks, and during the period, the mice freely eat and drink water; wherein the specific operation of the periodic 50mg / mL SiO2 suspension nasal drop is as follows: the periodic 50mg / mL SiO2 suspension nasal drop is carried out once every 3-4 days, and 30-50mu L of the periodic 50mg / mL SiO2 suspension nasal drop is taken each time; the intragastric administration dosage of ursodeoxycholic acid is that 100-200 mg of ursodeoxycholic acid is administered to each kilogram of mouse body weight. According to the invention, a triple induction strategy of silicon dioxide exposure, high fat diet and induction factor stimulation is adopted, two pathological characteristics of silicosis and atherosclerosis can be successfully and stably generated in a C57BL / 6J mouse, and relevance of silicosis and atherosclerosis can be simulated at the same time.

The application belongs to the technical field of biological medicine, and more particularly relates to nanoparticles TK-PSBs / CBD@Met, a preparation method therefor and application thereof. The nanoparticles TK-PSBs / CBD@Met are nanoparticles formed by wrapping cannabidiol and metformin with thione-modified lung surfactant biomimetic liposomes. In vitro experiments have confirmed that the nanoparticles TK-PSBs / CBD@Met can effectively inhibit the fibrosis process of BEAS-2B cells induced by silicon dioxide. Animal experiments have shown that the nanoparticles TK-PSBs / CBD@Met can significantly improve the damage to the lung tissue structure and abnormal deposition of collagen caused by SiO2 exposure, and alleviate the pathological progression of silicosis fibrosis.

The invention relates to the technical field of transformer air passage rods, and discloses an air passage rod for pouring a coil of a dry-type transformer and a production method and production equipment of the air passage rod. According to the technical scheme, polytetrafluoroethylene is modified through a sintering crystallization method, the production equipment is improved, and a supporting mechanism of the production equipment comprises an equipment shell; before use, a pipe of materials needing to be mixed is connected with an input pipe, a power source of a power motor is connected, at the moment, the power motor drives a driving column and a fixing column to rotate through a belt, the fixing column drives rotating fan blades to scatter the needed materials and disperse the materials to the inner wall of the equipment shell, and the materials slide downwards along the inner wall of the equipment shell; and in addition, the equipment adopts a whole-course closed design, so that the equipment can be used for filling and mixing and stirring at the same time, a sealing cover of the equipment does not need to be opened, a finished mixture does not need to be dug, glass fibers are prevented from entering the lungs of a person through respiration, and the labor intensity of workers is reduced. Deposition can be formed by workers for a long time, and occupational diseases similar to silicosis can be caused.

The invention discloses an application of a chemokine ligand 4 antibody in preparation of a medicine for treating silicosis, C-Cchemmokine ligand 4, namely the chemokine ligand 4 is called a CCL4 antibody for short, silicosis is lung diseases caused by long-term inhalation of free crystalline silicon dioxide particles in air, and is mainly characterized by inflammation and fibrosis. The treatment mechanism of silicosis and the side effects brought by the silicosis are very complex, the silicosis is progressive and irreversible and still has no curing scheme, so that the silicosis still has great threats to the life quality and the life time of silicosis patients, and the silicosis can damage the hematopoietic system of the organism besides causing inflammation and fibrosis, so that the silicosis cannot be cured. The invention discloses an inhibitor CCL4 antibody which can effectively relieve inflammation and fibrosis reaction caused by silicosis and can also recover the function of a hematopoietic system, and the number and function of hematopoietic stem progenitor cells are mainly influenced by the hematopoietic stem progenitor cells caused by silicosis caused by the hematopoietic stem progenitor cells.

The invention discloses application of inhibition of RUNX3 gene expression in preparation of medicines for preventing or treating silicosis, and belongs to the technical field of biological medicines. In-vivo and in-vitro silicosis models prove that the RUNX3 has high specificity expression in the silicosis process and is a key factor for driving disease progression. By inhibiting the expression of RUNX3 through a gene knock-down technology, silica-induced lung inflammation infiltration and collagenous fiber deposition can be significantly reduced, and the expression levels of key inflammatory factors (IL-1beta, IL-6 and TNF-alpha) and fibrosis indexes (Collagen I, Collagen III and Fibronectin) can be effectively down-regulated. Therefore, any substance capable of specifically inhibiting the expression of the RUNX3 gene, including but not limited to siRNA, shRNA, antisense oligonucleotide, ribozyme, microRNA and an inhibitor targeting the gene promoter thereof, can be used for developing the pharmaceutical composition for preventing or treating silicosis.

The application discloses a Shengfu decoction and a preparation method and application thereof, and a traditional Chinese medicine composition, which comprises ginseng, aconite, salvia miltiorrhiza and platycodon grandiflorum, and the ratio of the ginseng, the aconite, the salvia miltiorrhiza and the platycodon grandiflorum is 3:2:(3-4):(2-3) in mass fraction. The traditional Chinese medicine composition can effectively prevent and treat the symptoms of silicosis fibrosis. The pharmacology of the traditional Chinese medicine composition is that the ginseng has the effects of being sweet, slightly bitter and slightly warm, and can greatly supplement primordial qi, restore pulse and fix loss of consciousness, supplement the spleen and the lung, produce saliva and nourish blood, and calm the nerves and improve intelligence; the aconite is pungent, sweet, highly hot and toxic, and has the effects of restoring yang and saving from danger, supplementing fire and assisting yang, and dispelling cold and relieving pain; the two are matched to reduce toxicity and increase efficacy; the salvia miltiorrhiza can relieve lung fibrosis by eliminating oxygen free radicals, resisting lipid peroxidation, inhibiting collagen repair imbalance and resisting inflammation; and the platycodon grandiflorum has the effects of resisting inflammation, resisting viruses, protecting the liver, regulating immunity and resisting tumors.

The invention relates to the technical field of crushing, and discloses a concentrator shell recovery crushing device which comprises a crushing machine body, a feeding port is formed in the side face of the crushing machine body, a working cavity and a recovery part are formed below the crushing machine body, the recovery part is located in a space defined by the working cavity, and the recovery part comprises a rack; the bottom of the rack and the lower portion of the pulverizer body are fixedly installed, a recycling bin is rotationally connected to the interior of the rack, and the outer surface of the recycling bin is sleeved with a filtering piece. The smashing device for recycling the concentrator shell can effectively solve the problems that in the prior art, plastic dust is generated in the ABS plastic smashing process, silicosis is possibly caused by long-time accumulation, in addition, if the plastic dust continuously or frequently appears and is enough to form a mixture of flammable dust and air, explosion is possibly caused, and the service life of the plastic dust is prolonged. And threats are caused to personnel and equipment security.

The invention provides a method and equipment for preparing a light building material by separating free silicon dioxide from feldspar, and relates to the technical field of building material production, the method comprises the following steps: S1, removing impurities from feldspar: S11, performing hydraulic classification impurity removal: uniformly dispersing mineral separation tailings of granite mines and water according to the concentration of 7-20%, and pumping to a hydraulic classifier; -200-mesh silt slurry obtained by overflowing is collected and is subjected to belt type filtration removal; and grinding and screening the sand grains obtained by precipitation, and enabling the obtained particles to enter a subsequent process. According to the scheme, it is finally guaranteed that the final filler does not contain any crystalline silicon dioxide through deep separation of free silicon dioxide and a crystal transformation process, silicon lung diseases are completely eradicated from the source, and due to the low specific gravity characteristic of the material, the manufactured artificial stone plate is lighter in weight under the same size, and the cost is reduced. The composite material is especially suitable for dry-hanging outer walls and indoor decoration of high-rise buildings and super high-rise buildings, reduces building loads, and is a new-generation green building material.

The utility model relates to the technical field of cement grinding equipment, in particular to an automatic material cleaning device for an inner ring of a feeding cavity of a ball mill. Comprising a supporting rod located in the feeding cavity, one end of the supporting rod is fixed to a grinding inlet chute shell, the other end of the supporting rod extends towards the grinding head side and is obliquely arranged upwards, the other end of the supporting rod is connected with a scraping mechanism, and the scraping mechanism is in clearance fit with the top of the inner ring of the feeding cavity. According to the device, additional power does not need to be provided, sticky materials are automatically cleaned through autorotation of the ball mill, a user does not need to open an equipment access door to enter equipment to clean the sticky materials, dangerous operation such as limited space and high-place operation is avoided, and many safety risks such as high-place falling, hypoxia suffocation, high-temperature heatstroke, burying and silicosis are thoroughly eliminated; the environment pollution caused by dust overflow is effectively avoided, the sticky materials are not limited to be cleaned in a shutdown state, the sticky materials are prevented from being attached, solidified and hardened for a long time to form lump materials difficult to clean, and the labor intensity of post personnel is reduced.

The invention discloses a respiratory function training system for silicosis patients based on flexible electronic skin, and relates to the technical field of respiratory function training. A feedback instruction from the central processing unit is received through the feedback unit, and the instruction is converted into a feedback form capable of being perceived by a patient, so that the patient is guided to adjust the breathing depth, frequency and mode, it is ensured that the training process conforms to a personalized scheme, and the breathing function recovery effect is improved; the whole breathing training process is coordinated and managed through the training control unit, training is automatically started or paused according to the real-time breathing state of a patient, the training intensity and duration are dynamically adjusted to be matched with a personalized scheme, training safety indexes are monitored, training historical data are stored, and follow-up analysis and scheme optimization are facilitated. Therefore, the continuity, the safety and the rehabilitation effect of the training process are ensured to be maximized; patient experience is enhanced through a user interaction interface, requirements of different crowds are met, the rehabilitation trend is visually displayed through a progress chart, and the patient is helped to visually understand the progress of himself / herself.

The invention belongs to the technical field of biological medicine, and particularly relates to application of Ctss as a silicosis diagnosis marker and an inhibitor thereof. The invention finds and proves that the Ctss has high specific expression in a silicosis model for the first time, the expression level of the Ctss is positively correlated with the disease process, and the Ctss can be used as a potential biomarker for diagnosing silicosis. Further mechanism research shows that the Ctss can promote fibroblast activation and extracellular matrix protein synthesis, so that the pulmonary fibrosis process is driven. Targeted inhibition of Ctss is provided as a new strategy for treating silicosis, the effectiveness of the specific Ctss inhibitor LY3000328 is verified in an animal model, and lung inflammation and collagen deposition can be remarkably relieved. Therefore, the invention provides the application of the Ctss in preparation of silicosis diagnosis or evaluation products and the application of the Ctss inhibitor in preparation of anti-silicosis pulmonary fibrosis drugs, and provides a solution for early diagnosis and targeted therapy of silicosis.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from benidipine, folic acid substances and acceptable auxiliary materials. The ratio range of the benidipine to the folic acid is (2-10): (0.2-2.0) according to the content of the benidipine and the folic acid. The pharmaceutical composition has the advantages that the pharmaceutical composition can inhibit pulmonary fibrosis, can be provided for pulmonary fibrosis high-risk groups such as pulmonary tuberculosis, chronic bronchitis, interstitial pneumonia and silicosis, and is used for preventing or treating pulmonary fibrosis. In addition, the compound form of the pharmaceutical composition is beneficial to improving the curative effect, reducing the side effect and increasing the medication compliance.